JP2015512418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512418A5 JP2015512418A5 JP2015503627A JP2015503627A JP2015512418A5 JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5 JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015503627 A JP2015503627 A JP 2015503627A JP 2015512418 A5 JP2015512418 A5 JP 2015512418A5
- Authority
- JP
- Japan
- Prior art keywords
- scopolamine
- ketamine
- disorder
- medicament according
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 42
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 42
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 42
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 42
- 229960003299 ketamine Drugs 0.000 claims description 42
- 229960002646 scopolamine Drugs 0.000 claims description 42
- 230000037396 body weight Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 8
- 206010057666 Anxiety disease Diseases 0.000 claims description 4
- 206010012378 Depression Diseases 0.000 claims description 4
- 206010013982 Dysthymic disease Diseases 0.000 claims description 4
- 206010033666 Panic disease Diseases 0.000 claims description 4
- 206010039775 Seasonal affective disease Diseases 0.000 claims description 4
- 210000004304 Subcutaneous Tissue Anatomy 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000003895 major depressive disease Diseases 0.000 claims description 4
- 201000008895 mood disease Diseases 0.000 claims description 4
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000008839 post-traumatic stress disease Diseases 0.000 claims description 4
- 208000007979 Treatment-Resistant Depressive Disorder Diseases 0.000 claims description 3
- 206010012401 Depressive disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618212P | 2012-03-30 | 2012-03-30 | |
| US61/618,212 | 2012-03-30 | ||
| PCT/US2013/034524 WO2013149102A1 (en) | 2012-03-30 | 2013-03-29 | Compositions comprising scopolamine and ketamine in the treatment of depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Division JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512418A JP2015512418A (ja) | 2015-04-27 |
| JP2015512418A5 true JP2015512418A5 (pt-PT) | 2015-06-11 |
Family
ID=49261273
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503627A Pending JP2015512418A (ja) | 2012-03-30 | 2013-03-29 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018136350A Pending JP2018184440A (ja) | 2012-03-30 | 2018-07-20 | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150057306A1 (pt-PT) |
| EP (1) | EP2830604A4 (pt-PT) |
| JP (2) | JP2015512418A (pt-PT) |
| WO (1) | WO2013149102A1 (pt-PT) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643449A (zh) | 2013-03-15 | 2020-09-11 | 詹森药业有限公司 | S-盐酸氯胺酮的药物组合物 |
| EP3725307A1 (en) | 2014-09-15 | 2020-10-21 | Janssen Pharmaceutica NV | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| EP3297620A4 (en) | 2015-06-27 | 2019-01-09 | Shenox Pharmaceuticals, LLC | TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE |
| WO2017087691A1 (en) | 2015-11-17 | 2017-05-26 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2019099568A1 (en) * | 2017-11-14 | 2019-05-23 | Bexson Biomedical, Inc. | Systems, devices, formulations and methods for controlled drug delivery |
| SG11202005896WA (en) | 2017-12-22 | 2020-07-29 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3753557A4 (en) | 2018-02-15 | 2021-12-01 | National University Corporation Chiba University | PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES |
| TWI767133B (zh) * | 2018-08-02 | 2022-06-11 | 台灣微脂體股份有限公司 | 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途 |
| MX2021010683A (es) | 2019-03-05 | 2021-12-10 | Janssen Pharmaceuticals Inc | Esketamina para el tratamiento de la depresión. |
| WO2020232274A1 (en) * | 2019-05-15 | 2020-11-19 | Bexson Biomedical, Inc. | Ketamine formulation for subcutaneous injection |
| US20230256004A1 (en) * | 2020-07-09 | 2023-08-17 | Light Aqua Llc | Compositions and methods for treating mood disorders and circadian rhythm sleep disorders |
| CA3198795A1 (en) | 2020-11-18 | 2022-05-27 | Jeffrey Becker | Complexing agent salt formulations of pharmaceutical compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060646C (zh) * | 1993-06-07 | 2001-01-17 | 李举寿 | 戒毒注射液及其制造方法 |
| US8859585B2 (en) * | 2005-05-25 | 2014-10-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Scopolamine for the treatment of depression and anxiety |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
-
2013
- 2013-03-29 US US14/388,410 patent/US20150057306A1/en not_active Abandoned
- 2013-03-29 EP EP13767616.9A patent/EP2830604A4/en not_active Withdrawn
- 2013-03-29 WO PCT/US2013/034524 patent/WO2013149102A1/en active Application Filing
- 2013-03-29 JP JP2015503627A patent/JP2015512418A/ja active Pending
-
2016
- 2016-03-17 US US15/072,970 patent/US20170042878A1/en not_active Abandoned
-
2018
- 2018-07-20 JP JP2018136350A patent/JP2018184440A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512418A5 (pt-PT) | ||
| NZ604029A (en) | Methods of treating bladder cancer | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| WO2006098603A3 (en) | Composition comprising isoorientin for suppressing histamine | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| JP2017501154A5 (pt-PT) | ||
| JP2013541583A5 (pt-PT) | ||
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| JP2017061488A5 (pt-PT) | ||
| JP2017524721A5 (pt-PT) | ||
| MX2015016418A (es) | Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. | |
| WO2014100679A8 (en) | Stimulation and enhancement of regeneration of tissues | |
| JP2015512923A5 (pt-PT) | ||
| MX2010006724A (es) | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. | |
| JP2010538054A5 (pt-PT) | ||
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| JP2014517038A5 (pt-PT) | ||
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| CN104667073A (zh) | 治疗神经衰弱的中药 | |
| JP2015512439A5 (pt-PT) |